Administration of drug (Interferon-gamma 1-b) subcutaneously ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02609932 (ClinicalTrials.gov) | July 2016 | 11/11/2015 | Effect of IFN-? on Innate Immune Cells | Effect of Interferon-gamma 1-b on Innate Immune Cells | Chronic Granulomatous Disease | Drug: Administration of drug (Interferon-gamma 1-b) subcutaneously | University of Colorado, Denver | NULL | Completed | 18 Years | 60 Years | All | 20 | Phase 1 | United States |